Servier
22 Rue Garnier
Neuilly Sur Seine
92200
France
Website: http://www.servier.com/
Email: webmaster@servier.com
189 articles about Servier
-
Parkinson's disease: Servier and Oncodesign join forces to investigate new line of research
3/11/2019
Servier to be granted option to exclusively license one or several drug candidates as soon as they are approved to enter phase 1
-
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
2/21/2019
Amgen (NASDAQ: AMGN),Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
-
For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.
-
Servier Joins Embleema's Blockchain Health Consortium to Launch a Pilot Project for Blockchain
12/4/2018
Servier announced today that it has joined Embleema's Blockchain Health Consortium, a decentralized network based on Blockchain technology, as part of the launch of a pilot blockchain project within the Group.
-
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
-
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
-
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
-
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
-
Galapagos reports initiation of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in osteoarthritis patients
9/26/2018
Galapagos NV (Euronext & NASDAQ: GLPG) reports first dosing in the global ROCCELLA Phase 2 trial with GLPG1972/S201086 in knee osteoarthritis patients.
-
Servier and Poietis announce scientific partnership in 4D bioprinting of liver tissues
9/19/2018
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues.
-
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
-
As its acquisition by Takeda Pharmaceutical edges closer and closer, Shire reported a solid second-quarter.
-
The Chinese biopharma market is booming as more and more companies eye breaking into that rich market. Christophe Weber, chief executive officer of pharma giant Takeda, views its China programs as its second-biggest business behind the United States.
-
French biotech company Servier is setting up shop in Boston following its April deal to acquire Shire’s oncology business for $2.4 billion.
-
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
7/9/2018
PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab
-
Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018
6/14/2018
Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain
-
WeHealth by Servier joins forces with Peter Sheehan Diabetes Care Foundation in the fight against diabetes
6/12/2018
WeHealth by Servier and the Peter Sheehan Diabetes Care Foundation (PSDC Foundation) have today announced a new partnership to strengthen their efforts in the fight against diabetes
-
Axial Biotherapeutics Announces Neurology Scientific and Clinical Advisory Board
6/12/2018
Axial Biotherapeutics today announced the appointment of renowned researchers and thought leaders with expertise in neurology, Parkinson’s disease and regulatory strategy to its scientific and clinical advisory board.
-
Servier Announces Launch of Servier BioInnovation in the U.S.
6/6/2018
Senior R&D and Business Development and Licensing Appointments Announced